NCT02085148 2024-04-22
A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy
Bayer
Phase 1 Completed
Bayer
H. Lee Moffitt Cancer Center and Research Institute
Acrotech Biopharma Inc.
Merck Sharp & Dohme LLC